Imagion Biosystems Limited (IBXXF)

Market Cap	1.67M
Revenue (ttm)	1.65M
Net Income (ttm)	-1.28M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	554
Average Volume	7,696
Open	0.0100
Previous Close	0.0350
Day's Range	0.0100 - 0.0100
52-Week Range	0.0100 - 0.2560
Beta	1.80
RSI	44.23
Earnings Date	May 30, 2025

About Imagion Biosystems

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: IBXXF

Financial Performance

In 2024, Imagion Biosystems's revenue was 2.67 million, a decrease of -46.38% compared to the previous year's 4.97 million. Losses were -2.07 million, -83.43% less than in 2023.

Financial numbers in AUD